NCT03027362View on ClinicalTrials.gov

Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

January 15, 2020

Conditions
Depressive Disorder, Major
Interventions
OTHER

Cognitive behavioral therapy (CBT) and medication

Sixteen sessions over 14 weeks.

OTHER

Psychoeducation and medication

Trial Locations (1)

06511

Yale University, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03027362 - Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression | Biotech Hunter | Biotech Hunter